Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

FAB 117-HC

Next Previous
Drug Profile

FAB 117-HC

Alternative Names: FAB 117; FAB 117-HC; FIB 117; NeuroSave

Latest Information Update: 15 Feb 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ferrer Advanced Biotherapeutics; Histocell
  • Class Mesenchymal stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Spinal cord injuries

Most Recent Events

  • 15 Feb 2022 Phase I/II development in Spinal cord injuries is ongoing in Spain (EudraCT2015-005717-80) (NCT02917291)
  • 15 Feb 2022 Histocell announces intention to launch to FAB 117 HC for Spinal cord injuries before 2024 (Histocell pipeline, February 2022)
  • 01 Dec 2016 Phase-I/II clinical trials in Spinal cord injuries in Spain (Intrathecal) (EudraCT2015-005717-80)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top